[{"orgOrder":0,"company":"Brepco Biopharma","sponsor":"Piramal Critical Care","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dopamine","moa":"Adrenergic receptor-beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Brepco Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brepco Biopharma \/ Piramal Critical Care","highestDevelopmentStatusID":"15","companyTruncated":"Brepco Biopharma \/ Piramal Critical Care"}]

Find Clinical Drug Pipeline Developments & Deals for Dopamine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Neoatricon (dopamine hydrochloride) is a Beta-1 adrenergic receptor stimulator, small molecule drug candidate, which is indicated for the treatment of hypotension.

                          Product Name : Neoatricon

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 21, 2025

                          Lead Product(s) : Dopamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Piramal Critical Care

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank